Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 06-May-20 9:06 PM View:  | Al-Wakeel Yasir B. Chief Financial Officer | Neon Therapeutics, Inc. (NTGN) | 06-May-20 | Disposition | 196,965 | -- | -- | (100%) 196.97K to 0 | |
| 06-May-20 9:09 PM View: | Tepper Robert I Director 10% Owner | Neon Therapeutics, Inc. (NTGN) | 06-May-20 | Disposition | 9,741,640 | -- | -- | (100%) 9.74M to 0 | |
| 06-May-20 9:06 PM View: | Siegel Jolie VP, General Counsel | Neon Therapeutics, Inc. (NTGN) | 06-May-20 | Disposition | 161,821 | -- | -- | (100%) 161.82K to 0 | |
| 06-May-20 9:08 PM View: | Pfeffer Cary Director | Neon Therapeutics, Inc. (NTGN) | 06-May-20 | Disposition | -- | -- | -- | 0% -- | |
| 06-May-20 9:06 PM View: | Gaynor Richard President of R&D | Neon Therapeutics, Inc. (NTGN) | 06-May-20 | Disposition | 210,410 | -- | -- | (100%) 210.41K to 0 | |
| 06-May-20 9:07 PM View: | Lander Eric S Director | Neon Therapeutics, Inc. (NTGN) | 06-May-20 | Disposition | 134,000 | -- | -- | (100%) 134.0K to 0 | |
| 06-May-20 9:05 PM View: | O'Dowd Hugh President & CEO Director | Neon Therapeutics, Inc. (NTGN) | 06-May-20 | Disposition | 776,085 | -- | -- | (100%) 776.09K to 0 | |
| 06-May-20 9:08 PM View: | Sherwin Stephen A Director | Neon Therapeutics, Inc. (NTGN) | 06-May-20 | Disposition | 45,000 | -- | -- | (100%) 45.0K to 0 | |
| 25-Mar-20 5:28 PM View: | Access Industries Holdings ... 10% Owner | Neon Therapeutics, Inc. (NTGN) | 24-Mar-20 | Sale | 84,286 | $2.19 | $184,780.00 | (3%) 2.84M to 2.75M | |
| 25-Mar-20 5:28 PM View: | Access Industries Holdings ... 10% Owner | Neon Therapeutics, Inc. (NTGN) | 24-Mar-20 | Sale | 117,400 | $2.20 | $258,538.00 | (4%) 2.95M to 2.84M | |
| 25-Mar-20 5:28 PM View: | Access Industries Holdings ... 10% Owner | Neon Therapeutics, Inc. (NTGN) | 23-Mar-20 | Sale | 50,358 | $2.17 | $109,483.00 | (2%) 3.0M to 2.95M | |
| 23-Mar-20 9:00 PM View: | Access Industries Holdings ... 10% Owner | Neon Therapeutics, Inc. (NTGN) | 20-Mar-20 | Sale | 84,339 | $2.22 | $186,904.00 | (3%) 3.09M to 3.0M | |
| 23-Mar-20 9:00 PM View: | Access Industries Holdings ... 10% Owner | Neon Therapeutics, Inc. (NTGN) | 19-Mar-20 | Sale | 9,050 | $2.51 | $22,759.80 | (< 1%) 3.1M to 3.09M | |
| 02-Mar-20 6:39 PM View: | Siegel Jolie VP, General Counsel | Neon Therapeutics, Inc. (NTGN) | 29-Feb-20 | Payment of Exercise | 2,845 | $1.50 | $4,267.50 | (2%) 164.67K to 161.82K | |
| 02-Mar-20 6:38 PM View: | O'Dowd Hugh President & CEO Director | Neon Therapeutics, Inc. (NTGN) | 29-Feb-20 | Payment of Exercise | 9,783 | $1.50 | $14,674.50 | (1%) 785.87K to 776.09K | |
| 02-Mar-20 6:39 PM View: | Gaynor Richard President of R&D | Neon Therapeutics, Inc. (NTGN) | 29-Feb-20 | Payment of Exercise | 5,625 | $1.50 | $8,437.50 | (3%) 216.03K to 210.41K | |
| 02-Mar-20 6:39 PM View: | Al-Wakeel Yasir B. Chief Financial Officer | Neon Therapeutics, Inc. (NTGN) | 29-Feb-20 | Payment of Exercise | 4,891 | $1.50 | $7,336.50 | (2%) 201.86K to 196.97K | |
| 27-Feb-20 6:21 PM View: | Gaynor Richard President of R&D | Neon Therapeutics, Inc. (NTGN) | 25-Feb-20 | Payment of Exercise | 5,465 | $1.51 | $8,252.15 | (2%) 221.5K to 216.03K | |
| 27-Feb-20 6:21 PM View: | Al-Wakeel Yasir B. Chief Financial Officer | Neon Therapeutics, Inc. (NTGN) | 25-Feb-20 | Payment of Exercise | 5,385 | $1.51 | $8,131.35 | (3%) 207.24K to 201.86K | |
| 27-Feb-20 6:21 PM View: | Siegel Jolie VP, General Counsel | Neon Therapeutics, Inc. (NTGN) | 25-Feb-20 | Payment of Exercise | 5,334 | $1.51 | $8,054.34 | (3%) 170.0K to 164.67K | |
| 13-Jan-20 5:27 PM View: | Siegel Jolie VP, General Counsel | Neon Therapeutics, Inc. (NTGN) | 12-Jan-20 | Grant | 65,000 | -- | -- | 62% 105.0K to 170.0K | |
| 13-Jan-20 5:01 PM View: | Gaynor Richard President of R&D | Neon Therapeutics, Inc. (NTGN) | 12-Jan-20 | Grant | 65,000 | -- | -- | 42% 156.5K to 221.5K | |
| 13-Jan-20 5:20 PM View: | O'Dowd Hugh President & CEO Director | Neon Therapeutics, Inc. (NTGN) | 12-Jan-20 | Grant | 240,000 | -- | -- | 44% 545.87K to 785.87K | |
| 13-Jan-20 5:00 PM View: | Al-Wakeel Yasir B. Chief Financial Officer | Neon Therapeutics, Inc. (NTGN) | 12-Jan-20 | Grant | 65,000 | -- | -- | 46% 142.24K to 207.24K | |
| 27-Nov-19 5:01 PM View: | Gaynor Richard President of R&D | Neon Therapeutics, Inc. (NTGN) | 27-Nov-19 | Sale | 22,322 | $1.24 | $27,643.60 | (12%) 178.82K to 156.5K | |
| 27-Nov-19 5:01 PM View: | Gaynor Richard President of R&D | Neon Therapeutics, Inc. (NTGN) | 26-Nov-19 | Sale | 23,000 | $1.31 | $30,231.20 | (11%) 201.82K to 178.82K | |
| 25-Nov-19 5:25 PM View: | Gaynor Richard President of R&D | Neon Therapeutics, Inc. (NTGN) | 25-Nov-19 | Grant | 75,000 | -- | -- | 51% 146.82K to 221.82K | |
| 25-Nov-19 5:24 PM View: | Al-Wakeel Yasir B. Chief Financial Officer | Neon Therapeutics, Inc. (NTGN) | 25-Nov-19 | Grant | 75,000 | -- | -- | 112% 67.24K to 142.24K | |
| 25-Nov-19 5:25 PM View: | Siegel Jolie VP, General Counsel | Neon Therapeutics, Inc. (NTGN) | 25-Nov-19 | Grant | 75,000 | -- | -- | 250% 30.0K to 105.0K | |
| 27-Nov-19 5:01 PM View: | Gaynor Richard President of R&D | Neon Therapeutics, Inc. (NTGN) | 25-Nov-19 | Sale | 20,000 | $1.37 | $27,498.00 | (9%) 221.82K to 201.82K | |
| 01-Mar-19 6:17 PM View: | Al-Wakeel Yasir B. Chief Financial Officer | Neon Therapeutics, Inc. (NTGN) | 27-Feb-19 | Grant | 50,000 | -- | -- | 290% 17.24K to 67.24K | |
| 01-Mar-19 6:18 PM View: | O'Dowd Hugh President & CEO Director | Neon Therapeutics, Inc. (NTGN) | 27-Feb-19 | Grant | 100,000 | -- | -- | 22% 445.87K to 545.87K | |
| 01-Mar-19 6:18 PM View: | Ang Robert Chief Business Officer | Neon Therapeutics, Inc. (NTGN) | 27-Feb-19 | Grant | 20,000 | -- | -- | 8% 259.52K to 279.52K | |
| 01-Mar-19 6:20 PM View: | Siegel Jolie VP, General Counsel | Neon Therapeutics, Inc. (NTGN) | 27-Feb-19 | Grant | 30,000 | -- | -- | 100% 0 to 30.0K | |
| 01-Mar-19 6:19 PM View: | Gaynor Richard President of R&D | Neon Therapeutics, Inc. (NTGN) | 27-Feb-19 | Grant | 57,500 | -- | -- | 64% 89.32K to 146.82K | |
| 22-Aug-18 4:18 PM View: | O'Dowd Hugh President & CEO Director | Neon Therapeutics, Inc. (NTGN) | 20-Aug-18 | Option Exercise | 18,868 | $2.65 | $50,000.20 | 4% 427.0K to 445.87K | |
| 18-Jul-18 4:38 PM View: | Al-Wakeel Yasir B. Chief Financial Officer | Neon Therapeutics, Inc. (NTGN) | 17-Jul-18 | Option Exercise | 17,241 | $5.80 | $99,997.80 | 100% 0 to 17.24K | |
| 03-Jul-18 4:29 PM View: | Tepper Robert I Director 10% Owner | Neon Therapeutics, Inc. (NTGN) | 29-Jun-18 | Conversion | -- | -- | -- | 0% -- | |
| 29-Jun-18 4:16 PM View: | Hadley Harbor Master Invest... 10% Owner | Neon Therapeutics, Inc. (NTGN) | 29-Jun-18 | Conversion | 665,922 | -- | -- | 100% 0 to 665.92K | |
| 03-Jul-18 2:10 PM View: | Access Industries Holdings ... 10% Owner | Neon Therapeutics, Inc. (NTGN) | 29-Jun-18 | Conversion | 782,917 | -- | -- | 39% 2.0M to 2.78M | |
| 03-Jul-18 4:29 PM View: | Pfeffer Cary Director | Neon Therapeutics, Inc. (NTGN) | 29-Jun-18 | Conversion Duplicate | -- | -- | -- | 0% -- | |
| 03-Jul-18 2:10 PM View: | Access Industries Holdings ... 10% Owner | Neon Therapeutics, Inc. (NTGN) | 29-Jun-18 | Conversion | 999,998 | -- | -- | 100% 0 to 1000.0K | |
| 03-Jul-18 2:10 PM View: | Access Industries Holdings ... 10% Owner | Neon Therapeutics, Inc. (NTGN) | 29-Jun-18 | Purchase | 315,000 | $16.00 | $5,040,000.00 | 11% 2.78M to 3.1M | |
| 03-Jul-18 4:28 PM View: | Third Rock Ventures Iii, L.P. 10% Owner | Neon Therapeutics, Inc. (NTGN) | 29-Jun-18 | Conversion | 9,341,640 | -- | -- | 2335% 400.0K to 9.74M | |
| 03-Jul-18 2:10 PM View: | Access Industries Holdings ... 10% Owner | Neon Therapeutics, Inc. (NTGN) | 29-Jun-18 | Conversion | 999,998 | -- | -- | 100% 1.0M to 2.0M |
